The Russian company BIOCAD presented the results of studies of four drugs for the treatment of rheumatic diseases at the International Medical Congress in Seoul, iti.ru writes. During three years of treatment, 66% of patients with ankylosing spondylitis showed no progression of the disease on X-rays. In another study, more than 90% of patients who achieved remission maintained treatment gains up to week 52 after switching to maintenance therapy. The company also presented data from studies of two other drugs.

The Russian company BIOCAD presented the results of studies of four drugs for the treatment of rheumatic diseases at the International Medical Congress in Seoul, iti.ru writes. During three years of treatment, 66% of patients with ankylosing spondylitis showed no progression of the disease on X-rays. In another study, more than 90% of patients who achieved remission maintained treatment gains up to week 52 after switching to maintenance therapy. The company also presented data from studies of two other drugs.